Remote loading of minoxidil in nano-reservoirs leads to polymorphism and controlled release

Advancing Cancer Treatment Through Nanotechnology Driven Immunotherapy for Pancreatic Cancer

“…For instance, nanoparticulate drug delivery systems utilize various nanocarriers, such as liposomes, micelles, polymeric nanoparticles, gold nanoparticles, and quantum dots (Figure ). These nanocarriers have been extensively explored, leading to the development of several nanoproducts that outperform conventional chemotherapeutics .…”

“…Compared to emerging counterparts, such as biologics, one superior advantage of drug-loaded nanoparticles is their inherent stability, making them highly suitable for efficient and superior drug delivery . Besides the physicochemical approaches to engineer the nanoparticles, cellular targeting and modulation strategies can also improve the TME modification properties. , Moreover, engineered nanoparticles to regulate cells at TME, such as TAMs, regulatory T cells, MDSCs, TANs, and soluble immunosuppressive mediators, provide a feasible technique for transforming cold tumors into hot tumors. This spatiotemporal approach of modulating the nanoparticle properties can help in developing new nanomedicines for immunotherapy …”

“…has proposed the idea of controlled release nanomedicines (CRNM) that have the potential to target multiple pathways and modulate the spatio-temporal signaling from nanosystems at the site of action. In detail, CRNMs provides the opportunity to develop prolonged/activated drug delivery using nanosystems to the target site or fine-tune the delivery through multiple routes or modulate the delivery at the site of administration by exploring specific molecular pathways, and could be beneficial for the clinical advancements. , …”

“…But, depending on the tumor’s vascularization and kind, the EPR effect differs in patients . For instance, Nab-paclitaxel, a widely used nanotherapeutic in the treatment of PDAC, has been shown to reduce the tumor stroma through the interaction between the albumin-mediated secreted protein acidic and rich in cysteine (SPARC) domains . Furthermore, nanoparticle size can be modified to enhance their interaction with the tumor stroma.…”

“…In detail, CRNMs provides the opportunity to develop prolonged/activated drug delivery using nanosystems to the target site or fine-tune the delivery through multiple routes or modulate the delivery at the site of administration by exploring specific molecular pathways, and could be beneficial for the clinical advancements. The controlled release nanomedicines (CRNMs) provide the opportunity to develop prolonged/activated drug delivery using nanosystems to the target site or fine-tune the delivery through multiple routes or modulate the delivery at the site of administration by exploring specific molecular pathways and could be beneficial for clinical advancements. , …”